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analysis results were consistent with the base-case findings. ConClusions: Based 
on the willingness-to-pay threshold for end-of-life cancer drugs, ceritinib may be 
considered as a cost-effective option compared with other alternatives in patients 
who have progressed or are intolerant to crizotinib.
PCN183
A Cost-EffECtivENEss ANAlysis of AsPiriN iN thE PrimAry PrEvENtioN 
of CArdiovAsCulAr disEAsEs ANd ColorECtAl CANCEr
Soon S1, Chia WJ2, Redekop K3, Wee HL1
1National University of Singapore, Singapore, Singapore, 2National Cancer Centre of Singapore, 
Singapore, Singapore, 3Institute for Medical Technology Assessment, Erasmus Universiteit 
Rotterdam, DR Rotterdam, The Netherlands
objeCtives: This study aims to assess the cost-effectiveness of aspirin in the pri-
mary prevention of cardiovascular events (myocardial infarction (MI) and ischemic 
stroke (IS)) and colorectal cancer (CRC) in the low-risk general population in the 
United States (US). Methods: We developed and validated a Markov model to 
predict the number of primary events (MI, IS, or CRC) in US Caucasian males 
using established age-dependent risk data from the literature. Simulations were 
performed from the US healthcare system perspective using a starting cohort of 
non-smoking, non-diabetic Caucasian males aged 40 years old with low cardiovas-
cular risk (10-year risk < 5%) and normal CRC risks for the aspirin and no-aspirin 
arms. Annual cycles were simulated until 100 years old. Cost per quality-adjusted 
life year (QALY) and cost per life year (LY) were used as the primary outcome 
measures and clinical measures, numbers needed to treat (NNT) and numbers 
needed to harm (NNH), as secondary outcome measures. A 3% discount rate was 
applied to both costs and outcomes. Both deterministic and probabilistic sen-
sitivity analyses (PSA) were performed. Results: Aspirin was found to be the 
dominant strategy in the base-case analyses. NNT and NNH were 11.1 and 13.6 
respectively. One-way sensitivity analyses showed that the findings were highly 
sensitive to rates of hemorrhagic stroke, utilities of taking pill, aspirin’s effects 
on cardiovascular events, out-of-hospital MI fatality rates, and CRC risks. PSA 
showed that when willingness-to-pay (WTP) levels were varied from USD0 to 
USD100,000 per QALY gained, aspirin is likely to be cost-effective more than 80% 
of the time. ConClusions: Aspirin is likely to be cost-effective as a primary 
preventive agent. However, the finely balanced NNT and NNH made it premature 
to recommend aspirin for primary prevention of cardiovascular and CRC events 
in low-risk Caucasian males. Resources should be channeled towards conducting 
further studies to generate more precise model inputs.
PCN184
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objeCtives: To evaluate the cost-effectiveness of several sequential treatment 
strategies for chronic myeloid leukemia (CML) dependent on early molecular 
response (EMR) in the Austrian healthcare context. Methods: We adapted a pre-
viously developed Markov state-transition model to incorporate different treatment 
options (imatinib, dasatinib, nilotinib) dependent on achievement of EMR after 3 
months. We analyzed eight sequential treatment strategies using cohort simula-
tion over a lifelong time horizon. Model parameters were extracted from published 
literature, epidemiological and economic databases. We applied a 3% discount for 
health outcomes and costs. We analyzed 3 different base-case scenarios for patients 
not achieving an EMR after 3-months of imatinib treatment that were switched to a 
second-generation TKI, assuming three different effectiveness for these second-gen-
eration TKIs. Comprehensive sensitivity analyses were conducted. Results: The 
base-case analysis resulted in two non-dominated strategies: (1) imatinib, followed 
by nilotinib in case of non-achieved EMR at 3 months and dasatinib after treatment 
failure or imatinib continuation in case of achieved 3-month EMR and nilotinib 
after treatment failure; (2) nilotinib followed by its continuation in case of non-
achieved EMR at 3 months or switch to imatinib in case of achieved 3 month EMR 
and dasatinib after treatment failure. Depending on the scenario, strategy 2 resulted 
in an incremental cost-effectiveness ratio (ICER) of € 84,200/QALY, € 118,500/QALY 
or € 142,200/QALY gained compared to the baseline strategy. Remaining strategies 
were excluded due to dominance. Sensitivity analyses on generic pricing of imatinib 
showed that starting with a more potent second-generation TKI and switching to 
imatinib after an achieved EMR are the preferred strategies. ConClusions: Based 
on our analyses, we suggest nilotinib and its continuation for non-achieved EMR 
at 3 months or switch to imatinib after achieved 3-month EMR and dasatinib after 
treatment failure as a cost-effective strategy for Austria if the willingness-to pay 
threshold is at least around € 120,000/QALY.
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objeCtives: The nonavalent vaccine, by protecting against five additional onco-
genic HPV types, and nine HPV types in total (6, 11, 16, 18, 31, 33, 45, 52 and 58), is 
objeCtives: This study assessed, from a societal perspective, the cost-effective-
ness of idelalisib in combination with rituximab versus rituximab monotherapy 
for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). CLL 
is the most common leukemia in the Western world and is clinically character-
ized by peripheral blood B-cell lymphocytosis as well as lymphadenopathy, orga-
nomegaly, cytopenias and systemic symptoms in advanced stages. Methods: The 
cost-effectiveness model adopted a lifetime horizon with three health states: 1) 
pre-progression; 2) post-progression and 3) death. Patients enter in the model in 
the pre-progression state and in each cycle (1 week length) may survive without 
progression; advance to post-progression or die. Remission was not considered 
in the model: patients in post-progression state remain there until death. Costs 
and benefits were estimated for the Portuguese setting, and discounted at 5%, 
as recommended by national guidelines. Univariate and probabilistic sensitivity 
analyses assessed the robustness of results. Clinical efficacy, safety and utility data 
were based on published evidence, while survival curves were extrapolated using a 
Weibull function. Costs estimation was based on Diagnosis Related Group database, 
national legislation and opinions of an experts’ panel. Model outputs included life 
years gained, quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratios (ICERs). Results: Survival gains as well as direct medical costs were higher 
with idelalisib in association with rituximab compared to rituximab monotherapy, 
but costs related to adverse events and end-of-life care were lower. The ICER was 
of 32.702€ /QALY and 15.935€ /LY. Results were sensitive to the discount rates with 
an undiscounted ICER of 21.942 € . For other parameters univariate analyses ranged 
between 31.228€ /QALY and 34.176 € /QALY. PSA resulted in a median willingness to 
pay of 34.801€ /QALYs or 17.000€ /LY. ConClusions: Idelalisib plus rituximab in 
the treatment of relapsed/refractory CLL, compared with rituximab plus placebo, 
is cost-effective in Portugal.
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objeCtives: HPV vaccination is recommended in France for girls aged 11 to 14 with 
a catch-up from 15 to 19 years old. Though, with a cumulative coverage rate (VCR) of 
less than 20% in girls aged 16 years old for the HPV vaccine, France has one of the 
lowest VCR in Europe. The objective of the present study is to estimate the burden 
that would be averted by reaching in France the VCR currently observed in several 
EU countries. Methods: A dynamic transmission model including a wide range 
of health and cost outcomes related to cervical, anal, vulvar, vaginal diseases and 
genital warts, was adapted to French setting. The health outcomes resulting from 
the vaccination of girls with quadrivalent HPV vaccine was assessed according to 
two different vaccine coverage rates: (i) the 2014 cumulative coverage rate in girls 
aged 16 years old of 17.2% (reported by the InVS in July 2014) (ii) a VCR of 70% as 
observed in several European countries. Results: The analyses demonstrated that 
reaching in France a VCR comparable to those observed in other European countries 
would lead to avert additional 3,873,070 genital warts, 582,339 CIN2/3, 78,899 cervical 
cancers, 1,253 vaginal cancers, 1,756 vulvar cancers, and 17,993 anal cancers (includ-
ing 4,774 in males) over 100 years. Overall, 27,222 deaths from HPV cancers could 
be averted by increasing the VCR at 70%. ConClusions: The present study shows 
that the suboptimal HPV vaccination coverage rate observed in France is linked 
with a tremendous loss of opportunity for the French population. Even though the 
applied VCR is not representative of the VCR of the entire targeted population, it 
is clear that benefits of HPV vaccination are still undermined. In a context where 
cancer is a health priority in France, combined efforts to improve HPV vaccination 
coverage rate must be pursued.
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objeCtives: To assess the cost-effectiveness of ceritinib versus alternatives in 
patients who discontinue treatment with crizotinib in anaplastic lymphoma kinase-
positive (ALK+) non-small cell lung cancer (NSCLC) from a Canadian healthcare 
perspective. Methods: A partitioned survival model with three health states (pro-
gression-free, progressive, and death) was developed to compare ceritinib versus 
other alternatives in patients with ALK+ NSCLC who were previously treated with 
an ALK inhibitor. Comparators were chosen based on reported utilization from a 
retrospective Canadian chart study; comparators were pemetrexed, best-support-
ive care (BSC) and historical control. Progression-free survival and overall survival 
for ceritinib were estimated using data from reported single-arm clinical trials 
(ASCEND-1(NCT01283516) and ASCEND-2(NCT01685060)). Survival data for compara-
tors were obtained from published clinical trials in general NSCLC population and 
from a Canadian retrospective chart study in ALK+ patients treated with crizotinib. 
Parametric models were used to extrapolate outcomes beyond trial period. Drug 
acquisition, administration, resource use and adverse event (AE) costs were obtained 
from public databases. Utilities for health states and disutilities for AEs based on 
EQ-5D were derived from literature. Incremental costs per quality-adjusted life year 
(QALY) gained were estimated. Univariate and probabilistic sensitivity analyses were 
performed. Results: Over 4 years, ceritinib was associated with 0.86 QALYs and 
total direct costs of $89,740 for post-ALK population. The incremental cost per QALY 
was $149,117 comparing ceritinib vs. BSC, $80,100 vs. pemetrexed, and 104,436 vs. 
historical controls. Additional scenarios included comparison to docetaxel with an 
ICER/QALY of $149,780 and utility scores reported from PROFILE 1007, with a reported 
ICER/QALY ranging from $62,543 vs. pemetrexed to $119,735 vs. BSC. Sensitivity 
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objeCtives: The aim of this study is to compare the total cost of subcutaneous 
trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer 
patients from the R. Macedonia. Recent studies suggest that SC-TRA has a pharma-
cokinetic profile and efficacy non-inferior to standard IV-TRA and is a valid alternative 
for the treatment of eligible breast cancer patients. Methods: A cost-minimization 
analysis was performed using data from prior prospective time-motion study. Total 
time and cost of both types of TRA administration were quantified in a time horizon 
of over 18 cycles therapy course.The total of 169 patients (mean weight 74.20 kg) (300 
observed episodes) from two oncology clinics were enrolled. Patients were HER2+ and 
received the drug in the adjuvant (132 patients) or first line metastatic (37 patients) 
setting. Health care resources included drug treatment, patient’s room and chair time 
treatments, active healthcare professional time and consumables. Non-health care 
resources encompassed patients’ transport. The model accounted the 3%wastage of 
IV-TRA administration. Unit costs were obtained utilizing official (government and 
hospital pharmacy) publicly available data and they were expressed in Euro 2015, with 
no discount. Results: Direct medical costs per (mean weight) patient were € 30 500 
for IV-TRA and € 30 102 for SC-TRA. The mean total costs per patient of IV compared 
to SC administratuin of TRA over the full course of treatment were € 30 695 and € 30 
106, respectively. SC-TRA incurred less non-drug related cost (€ 4,20) than IV-TRA 
(€ 196). The results of the model were most sensitive to patient weight and % of wast-
age in IV treated patients. Mean cost saving per patient over a full treatment course 
for SC administration was € 589,2. Mean savings (preparation and administration) in 
time with SC-TRA were 47 min. ConClusions: SC-TRA can be time and cost-saving 
therapy for HER2+ breast cancer patients from the R. Macedonia.
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objeCtives: To determine the preferable treatment scheme for breast cancer (BC) 
from the pharmacoeconomic perspective by the comparison of subcutaneous (SC) 
and intravenous (IV) administration. Methods: The following pharmacoeconomic 
methods were used: cost-minimization analysis, budget impact analysis. Results: 
For cost-minimization analysis the following costs were included: cost of testing on 
tumor expression of HER2, the main drug therapy, concomitant therapy (medical 
services and drugs), introduction, services provided by medical personnel and the 
conditions of administration (in case of hospitalization or outpatient). Total costs per 
1 patient with BC for treatment course with trastuzumab for subcutaneous admin-
istration were 1 314 181 RUB/21 863 EUR and 1 503 716 RUB/25 016 EUR of trastu-
zumab for IV administration. Cost-minimization analysis revealed treatment change 
from trastuzumab for IV administration on trastuzumab for SC administration gave 
economy of 189 535 RUB/3 153 EUR per 1 patient for treatment course. According 
to budget impact analysis it was revealed that trastuzumab for SC administration 
allows to make economy of 175 508 955 RUB/2 919 796 EUR. ConClusions: During 
cost-minimization analysis it is determined that trastuzumab for IV allows to obtain 
economy compared with IV dosage form. Budget impact analysis reveals that change 
of BC treatment from trastuzumab for IV administration on trastuzumab for SC one 
give monetary economy.
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objeCtives: To determine the most preferable from the pharmacoeconomic per-
spective treatment scheme of follicular lymphoma (FL) treatment with rituximab for 
subcutaneous (SC) and intravenous (IV) administration. Methods: For this objective, 
the following pharmacoeconomic methods were used: cost-minimization analysis, 
budget impact. Results: The following costs were calculated for cost-minimization 
analysis: the main drug therapy, concomitant therapy, including medical services 
and medicines, administration, services provided by medical personnel and the 
conditions of administration (outpatient or hospitalization). According to the cost 
analysis it was determined that cost of FL treatment equals 3 534 687 RUB/ 58 803 
EUR under IV administration and 3 498 840 RUB/58 207 EUR under SC one. Cost-
minimization analysis revealed that rituximab for SC administration compared with 
IV one gives economy of 35 847 RUB/ 596 EUR per one patient for treatment course. 
During budget impact analysis it was determined that rituximab for SC administra-
tion gives 177 083 678 RUB/ 2 945 994EUR economy for treatment course of all patients 
in Russia. ConClusions: According to cost-minimization analysis, subcutaneous 
dosage form of rituximab allows to obtain economy compared with intravenous form. 
Budget impact analysis shows that rituximab for subcutaneous administration allows 
to make economy.
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expected to prevent an even broader spectrum of HPV-related cancers and other 
diseases and in particular, 90% of cervical cancers. This objective of this study was to 
estimate the incremental public health impact of a girls-only vaccination program 
with that of a universal vaccination program with a nonavalent human papillo-
mavirus vaccine in Germany as compared to the current girls-only vaccination 
with a quadrivalent HPV vaccine (6/11/16/18). Methods: A dynamic transmission 
model of HPV infection and the related diseases was calibrated to the German 
epidemiological data. Up to 70% of cervical cancer cases were attributed to HPV 
16/18 for the quadrivalent vaccine, and an additional 20% to the five additional 
types included in the nonavalent vaccine. In the base case, a two dose vaccination 
program with lifelong protection and a cumulative vaccination coverage rate of 
55.6% was assumed. Sensitivity analyses were conducted. Results: The findings 
of the analyses indicate that girls-only vaccination with the nonavalent vaccine 
has the potential to: i) reduce the incidence of HPV16/18/31/33/45/52/58 -related 
cervical cancer by 73% after 100 years, relative to 57% for the quadrivalent vaccine 
and , ii) prevent an additional of 345,627 cases of CIN2/3 and 25,566 cases of cervical 
cancer over 100 years. When vaccination of girls with the nonavalent vaccine was 
extended to boys, the cumulative reduction over 100 years in the incident cases 
was 498,007 and 39,489 of CIN2/3 and cervical cancer respectively. ConClusions: 
The introduction of a nonavalent HPV vaccine immunization program in Germany 
is estimated to significantly reduce the public health impact of cervical and other 
HPV-related diseases.
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objeCtives: Evidence suggests that response-guided neoadjuvant chemotherapy 
(RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestro-
gen receptor positive/human epidermal growth factor receptor-2 negative (ER+/
HER2-) breast cancer patients. We estimated the expected cost-effectiveness and 
resource requirements of implementing RG-NACT with MRI vs. conventional-NACT 
for treatment of ER+/HER2- breast cancers in the Netherlands (NL). Methods: A 
Markov-model was developed to analyse the incremental costs/QALY from a hos-
pital perspective over a 5-year time horizon. Health services required (MRI scans 
performed, MRI technologists, breast radiologists and confirmatory scans) for and 
health outcomes (prevented relapses, prevented deaths, patients with adverse 
events or contraindications and MRI technologists with adverse events) of imple-
menting RG-NACT were estimated via resource modelling analysis considering the 
current (4%) and a full implementation (100%) scenario in the Dutch population of 
ER+/HER2- breast cancer women (n= 6306). Results: RG-NACT is expected to gener-
ate 0.001 and 0.07 QALYs and save € 8 and € 341 costs for the 4% and 100% implemen-
tation scenarios respectively. At current implementation rate, 213 MRI examinations, 
273 MRI technologists and 1 breast radiologist are required to prevent 0.4 relapses 
and 6 cancer deaths. At full implementation, a 25-fold increase in MRI examina-
tions is projected, requiring ~5 times higher MRI utilization and 6560 additional MRI 
technologists, which is expected to prevent 10 additional relapses (+2400%) and 169 
cancer deaths (+2400%). Increasing implementation rates markedly increased the 
number of confirmatory scans (+901), contraindications (+932) and MRI technolo-
gists experiencing adverse events (+1706) by 25-fold, and decreased the number 
of patients with adverse events (-29) by 1.3-fold. ConClusions: RG-NACT likely 
dominates conventional-NACT at current and full implementation rates. Full imple-
mentation generates a 25-fold increase in additional health benefits, but requires 
MRI capacity in the Netherlands to be increased 5-fold, which is challenging given 
a shortage of MRI technologists.
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objeCtives: The main objective for conducting this study was to evaluate economic 
evaluation through the cost-effectiveness study of oral chemotherapy regimens 
we choose vinorelbine oral capsule plus oral capecitabine versus docetaxel iv plus 
oral capecitabine in treatment of metastatic breast cancer, in the Egyptian patients 
previously treated with anthracycline, from the national fund perspective over a 
time horizon of 3 years. Methods: A cost-effectiveness analysis from the perspec-
tive of the Ministry of Health and Population was conducted. A Markov model was 
applied with three health states. Utility data were incorporated in the model to make 
adjusted results. Costs used were the local ones according to the national fund list. 
Discounting was applied at 3.5% annually both on costs and benefits. The results 
obtained were in term of ICER and number of QALYs. Robustness of our findings 
was checked using sensitivity analyses. Results are expressed in QALYs Results: 
During the three-year time horizon, the total cost for oral chemotherapy regimen 
vinorelbine oral plus capsitabine was associated with a 2.46QALY gained. The total 
for docetaxel IV. was associated with 0.84 QALY gained.That yields a difference of 
and 1.62 in QALY. The oral chemotherapy regimen( Vinorelbine oral plus capsitabine 
is economically dominating the docetaxel strategy, producing more benefit at a 
lower cost. The one-dimensional sensitivity analysis indicated that the overall sur-
vival medians of both drugs had the largest impact on the results. When conducting 
sensitivity analysis using plausible ranges, Vinorelbine oral remained economically 
dominant in all cases. ConClusions: The introduction of oral chemotherapy regi-
men in metastatic breast cancer vinorelbine oral to the national fund Pay-at-The-
Expense-of-the-State (PTES) system was likely be cost saving based strictly from 
its perspective.
